Hints and tips:
...In 2019 one of Asia’s three species, the tri-spine horseshoe crab, was listed as endangered by the International Union for Conservation of Nature....
...Bourla’s ascent to the top job at Pfizer began nearly 30 years ago, when he joined its Greek animal health unit....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...His ascent to the top of one of the US’s foremost drugmakers is the kind of story that is all too rare in corporate America....
...We can move faster than pharma.” Hope for sickle cell Victoria Gray had been ill for all of her 34 years....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...There is a new pharmaceuticals giant in town....
...Shares in Enanta Pharma, which helped develop the AbbVie drug, rose 10 per cent to $51.31....
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
...Behind his meteoric ascent was his audacity and enthusiasm for the biosimilar industry, his aides say....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Examples include Astellas Pharma of Japan’s $3.8bn acquisition of OSI Pharmaceuticals in the US, and Korea National Oil’s $2.8bn deal with Britain’s Dana Petroleum....
...The S&P 500 in New York rose 0.4 per cent to a five month high as traders welcomed the Fed’s minutes and news of another M&A deal – this time Pfizer’s purchase of King Pharma for $3.6bn....
...One simple amendment would cut out pharmaceuticals from the new remedial regime by specifically articulating a favourable stance toward injunctive relief and the traditional standards of damages on pharma...
International Edition